| Thrombolytics. | |
| | |
MedLine Citation:
|
PMID: 1576039 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Thrombolytic therapy is the most recent advance in the treatment of acute myocardial infarction. Several research trials have been conducted worldwide in the last decade that have established that thrombolytic therapy has reduced mortality 50%, reduces the size of the infarction, improves left ventricular function, and reduces the incidence and severity of congestive heart failure. The three most commonly used thrombolytic agents at this time are streptokinase, tissue plasminogen activator, and anisoylated plasminogen-streptokinase activator complex. All three agents can be administered through a peripheral intravenous. Recent research results have reported similar efficacy on 5-week mortality of all three agents. Careful assessment of prospective patients is essential since bleeding complications are the most serious side effect of this therapy. Nursing care of a patient undergoing thrombolytic therapy includes careful assessment of the patient for contraindications in the patient's medical history, assessment of potential allergic and bleeding complications, and evaluation of the reperfusion markers. Patients are subsequently treated with anticoagulants, aspirin, or dipyridamole. It appears that thrombolytic therapy will become increasingly available to all patients with a diagnosis of suspected acute myocardial infarction. At present, treatment with thrombolytic agents is less available in the United States compared to Europe. |
| | |
Authors:
|
C L Ostrow |
Related Documents
:
|
1555479 - Is survival in acute myocardial infarction related to thrombolytic efficacy or the open... 20825889 - Do we need echocardiography before commencing thrombolytic therapy? 10348969 - Thrombolysis versus primary percutaneous transluminal coronary angioplasty for acute my... 2916879 - Feasibility and safety of emergency interhospital transport of patients during early ho... 1623119 - Exploration of rapid bedside monitoring of coagulation and fibrinolysis parameters duri... 1900139 - Pericardial effusion after intravenous recombinant tissue-type plasminogen activator fo... 6111609 - Myxoma masquerading as polyarteritis nodosa. 18382259 - Using devices for physiologic monitoring in heart failure. 23184309 - Interrelation between myocardial oxidative metabolism and diastolic function in patient... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: AACN clinical issues in critical care nursing Volume: 3 ISSN: 1046-7467 ISO Abbreviation: AACN Clin Issues Crit Care Nurs Publication Date: 1992 May |
Date Detail:
|
Created Date: 1992-06-09 Completed Date: 1992-06-09 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9009969 Medline TA: AACN Clin Issues Crit Care Nurs Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 423-36 Citation Subset: N |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anistreplase
/
therapeutic use Clinical Trials as Topic Humans Myocardial Infarction / drug therapy* Streptokinase / therapeutic use Thrombolytic Therapy* / contraindications, nursing Tissue Plasminogen Activator / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
81669-57-0/Anistreplase; EC 3.4.-/Streptokinase; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Nitrates.
Next Document: Angiotensin-converting enzyme inhibitors.